BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, April 24, 2024
Home
»
Newsletters
» BioWorld
BioWorld
July 2, 2009
View Archived Issues
No Buyout, but Acorda Banks $110M in Fampridine-SR Deal
It wasn't the acquisition some investors had hoped for, but Acorda Therapeutics Inc. hardly could have asked for better terms in its ex-U.S. licensing deal for multiple sclerosis drug Fampridine-SR. (BioWorld Today)
Read More
Myriad's Lowered Guidance Casts Pall over Spin-off Debut
Read More
Risk Genes for Schizophrenia Aplenty; Bipolar Shares Some
Read More
Biotech Survival Game Prompts CombinatoRx, Neuromed Merger
Read More
Holiday Notice
Read More
Awaiting FDA Action on Zevalin, Spectrum Seeks to Raise $21M
Read More
Clinic Roundup
Read More
Other News To Note
Read More